X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11571) 11571
Book Chapter (327) 327
Newspaper Article (135) 135
Newsletter (58) 58
Magazine Article (34) 34
Book / eBook (11) 11
Conference Proceeding (6) 6
Streaming Video (5) 5
Dissertation (4) 4
Web Resource (4) 4
Government Document (3) 3
Reference (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10346) 10346
science & technology (8880) 8880
life sciences & biomedicine (8516) 8516
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6658) 6658
oncology (4520) 4520
hematology (4462) 4462
male (4096) 4096
female (3844) 3844
imatinib mesylate (3633) 3633
chronic myeloid leukemia (3584) 3584
middle aged (3319) 3319
adult (3302) 3302
leukemia (3175) 3175
benzamides (2928) 2928
antineoplastic agents - therapeutic use (2890) 2890
pyrimidines - therapeutic use (2648) 2648
leukemia, myelogenous, chronic, bcr-abl positive - genetics (2632) 2632
leukemia, myelogenous, chronic, bcr-abl positive - pathology (2341) 2341
piperazines - therapeutic use (2263) 2263
aged (2251) 2251
protein kinase inhibitors - therapeutic use (1741) 1741
treatment outcome (1715) 1715
hemic and lymphatic diseases (1620) 1620
imatinib (1587) 1587
fusion proteins, bcr-abl - genetics (1576) 1576
cancer (1533) 1533
animals (1456) 1456
leukemia, myelogenous, chronic, bcr-abl positive - therapy (1201) 1201
adolescent (1200) 1200
antineoplastic agents - pharmacology (1199) 1199
research (1187) 1187
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (1149) 1149
care and treatment (1148) 1148
mutation (1089) 1089
pyrimidines - pharmacology (1059) 1059
protein-tyrosine kinases - antagonists & inhibitors (1031) 1031
apoptosis (1012) 1012
drug resistance, neoplasm (973) 973
kinases (973) 973
tyrosine (962) 962
dasatinib (956) 956
antineoplastic agents - adverse effects (913) 913
piperazines - pharmacology (904) 904
apoptosis - drug effects (891) 891
abridged index medicus (883) 883
pyrimidines - adverse effects (871) 871
cell line, tumor (862) 862
prognosis (860) 860
drug therapy (844) 844
mice (840) 840
stem cells (837) 837
genetic aspects (829) 829
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (810) 810
cml (808) 808
pyrimidines - administration & dosage (802) 802
antineoplastic combined chemotherapy protocols - therapeutic use (796) 796
k562 cells (788) 788
protein kinase inhibitors - pharmacology (784) 784
fusion proteins, bcr-abl - metabolism (768) 768
aged, 80 and over (760) 760
analysis (755) 755
young adult (751) 751
myeloid leukemia (731) 731
philadelphia chromosome (728) 728
health aspects (703) 703
fusion proteins, bcr-abl - antagonists & inhibitors (702) 702
cell biology (696) 696
medicine & public health (696) 696
remission induction (696) 696
antineoplastic agents (692) 692
hematology, oncology and palliative medicine (687) 687
proteins (679) 679
pharmacology & pharmacy (673) 673
antineoplastic agents - administration & dosage (664) 664
piperazines - administration & dosage (648) 648
bcr-abl (647) 647
piperazines - adverse effects (622) 622
transplantation (620) 620
leukemia, myelogenous, chronic, bcr-abl positive - mortality (618) 618
chronic myelogenous leukemia (615) 615
drug resistance (615) 615
antimitotic agents (609) 609
bone marrow (600) 600
drug resistance, neoplasm - genetics (596) 596
chemotherapy (595) 595
gene expression (578) 578
leukemia, myelogenous, chronic, bcr-abl positive - complications (578) 578
child (570) 570
signal transduction (535) 535
biochemistry & molecular biology (530) 530
cell proliferation - drug effects (517) 517
follow-up studies (517) 517
time factors (517) 517
dose-response relationship, drug (512) 512
interferon-alpha - therapeutic use (511) 511
patients (508) 508
risk factors (497) 497
protein kinase inhibitors - adverse effects (496) 496
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (487) 487
neoplasms (484) 484
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11629) 11629
Japanese (241) 241
Chinese (160) 160
French (69) 69
German (63) 63
Russian (57) 57
Spanish (57) 57
Polish (30) 30
Hungarian (23) 23
Portuguese (22) 22
Italian (18) 18
Czech (15) 15
Danish (13) 13
Swedish (5) 5
Dutch (4) 4
Slovak (4) 4
Finnish (3) 3
Hebrew (3) 3
Norwegian (3) 3
Ukrainian (3) 3
Croatian (2) 2
Korean (2) 2
Romanian (2) 2
Nauru (1) 1
Serbian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development | Index Medicus
Journal Article
Nature (London), ISSN 1476-4687, 01/2010, Volume 463, Issue 7280, pp. 501 - 506
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Transplantation, Heterologous | Piperazines - chemistry | Pyrimidines - chemistry | Pyrimidines - metabolism | Antineoplastic Agents - metabolism | Mass Spectrometry | Bone Marrow Transplantation | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Binding Sites | Disease Models, Animal | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Crystallization | Antineoplastic Combined Chemotherapy Protocols | Models, Molecular | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Mutation - genetics | Imatinib Mesylate | Piperazines - pharmacology | Fusion Proteins, bcr-abl - genetics | Animals | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Benzamides | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Nilotinib | Dasatinib | Drug resistance in microorganisms | Usage | Nuclear magnetic resonance spectroscopy | Research | Chronic myeloid leukemia | X-ray crystallography | Chromosome abnormalities | Gene mutations | Analysis | Genetic aspects | Diagnosis | Binding proteins | Drug therapy | Health aspects | Proteins | Studies | Competition | Enzymes | E coli | Kinases | Drug resistance | Crystal structure | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 02/2014, Volume 32, Issue 5, pp. 415 - 423
... MR4.5 which was defined as 4.5 log reduction of BCR-ABL on the international scale (IS) and determined by reverse transcriptase polymerase chain reaction in two consecutive analyses... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
Cancer Letters, ISSN 0304-3835, 2015, Volume 360, Issue 2, pp. 245 - 256
Journal Article